Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT03166176 Withdrawn - Solid Tumor Clinical Trials

Phase II Trial of Vistusertib(AZD2014) Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy

TSC1/2_SC
Start date: March 2018
Phase: Phase 2
Study type: Interventional

Patients with TSC1/2 mutated refractory solid cancer will receive vistusertib(AZD2014) monotherapy. Study-arm is composed of 27 patients. Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle as a monotherapy

NCT ID: NCT03147976 Withdrawn - Solid Tumor Clinical Trials

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

Start date: May 2, 2018
Phase: Phase 2
Study type: Interventional

This is a phase 2 study of AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations resulting in MET exon 14 skipping.

NCT ID: NCT02656849 Withdrawn - Solid Tumor Clinical Trials

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

Start date: February 2016
Phase: Phase 2
Study type: Interventional

This research study is studying whether a new experimental cancer study drug BAY 1000394 will be helpful in treating solid tumor cancer with an abnormality in one of the following genes: Mcl-1, Myc or CCNE.

NCT ID: NCT02101164 Withdrawn - Solid Tumor Clinical Trials

Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

Start date: November 2014
Phase: Phase 4
Study type: Interventional

This study will estimate the total time for the preparation and administration of denosumab and the total time for the preparation and administration of pamidronate.

NCT ID: NCT01565421 Withdrawn - Cancer Clinical Trials

Efficacy Study of Maintenance Therapy for Ovarian Cancer Patients

Start date: September 2008
Phase: Phase 2
Study type: Interventional

This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.

NCT ID: NCT01007422 Withdrawn - Pain Clinical Trials

Opioids Titration in Hospice Patients

Start date: June 2008
Phase: N/A
Study type: Observational

RATIONALE: Opioids lessen pain caused by cancer. Titration of opioids in the hospice setting is suboptimal due to numerous barriers. Order sets may help to provide timely and effective medical and pharmaceutical intervention. PURPOSE: The purpose of this study was to identify barriers to good pain control in the hospice setting and to develop an order set that would safely address these barriers.

NCT ID: NCT00820768 Withdrawn - Solid Tumor Clinical Trials

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Start date: April 1, 2012
Phase: Phase 1
Study type: Interventional

To determine MTD and DLT of ABI-010 given weekly every three weeks followed by one week of rest (Cycle 1). Determine MLD and DLT in combination with ABI-007; to characterize the toxicities of ABI-010 alone and in combination with ABI-007.

NCT ID: NCT00753740 Withdrawn - Cancer Clinical Trials

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Start date: September 2008
Phase: Phase 2
Study type: Interventional

This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.

NCT ID: NCT00624962 Withdrawn - Leukemia Clinical Trials

Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors

Start date: March 2006
Phase: N/A
Study type: Interventional

RATIONALE: Tubefeeding may help maintain good nutrition and lessen weight loss in younger patients receiving chemotherapy for cancer. PURPOSE: This clinical trial is studying how well tube feedings work in younger patients receiving chemotherapy for newly diagnosed acute myeloid leukemia, myelodysplastic syndrome, or high-risk solid tumors.

NCT ID: NCT00499668 Withdrawn - Lymphoma Clinical Trials

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Start date: August 2007
Phase: N/A
Study type: Interventional

RATIONALE: Antiemetic drugs, such as aprepitant and ondansetron, may help lessen nausea and vomiting caused by opioids. It is not yet known whether aprepitant is more effective than ondansetron in treating nausea and vomiting caused by opioids in patients with cancer. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to ondansetron in treating nausea and vomiting caused by opioids in patients with cancer.